Live
Endpoints NewsIncyte CEO sees $2B Vega deal aiding a post-Jakafi futureClinical OMICsCortical On/Off Switch Provides Sleep Benefits to Awake MiceClinical OMICsGLP-1 Drugs Linked to Lower Rates of Substance Use DisordersEndpoints NewsCity Therapeutics gets $99M to gather data on three RNAi medicinesClinical OMICsProPure™ Endotoxin-Free Proteins for Reliable Cancer ResearchClinical OMICsTARGA Imager Enables High-Resolution Imaging of Neurodevelopmental ModelsBioPharma DiveRoche stakes $700M on Nurix’s protein-degrading drugClinical OMICsSignatera™ as a Pan-Cancer Decision-Making Tool to Illuminate the Care PathwayEndpoints NewsGoHealth files for bankruptcy, as Medicare Advantage insurers pull backAgilentHow Investors May Respond To Agilent Technologies (A) Expanding AI-Enabled Lab Solutions And Oncology Diagnostics - simplywall.stAgilentHow Investors May Respond To Agilent Technologies (A) Expanding AI-Enabled Lab Solutions And Oncology Diagnostics - simplywall.stBioPharma DiveTango data add to growing momentum for pancreatic cancer drugs
BioWorld Apr 24, 2026

Shanghai Meiyue Biotech Development presents new molecular glue degraders

Shanghai Meiyue Biotech Development presents new molecular glue degraders

Original
Body unavailable. Use the original source.